In this episode, Dr. Hadzic breaks down the latest meta-analysis on transfusion strategies in traumatic brain injury patients. Are we under-transfusing and compromising brain recovery? Evidence now points to a liberal transfusion strategy with a 9 g/dL threshold improving neurologic outcomes, without increasing mortality. But watch out: ARDS risk rises. Tune in to hear why current guidelines may need a serious update and how this could shift your ICU practice.

Where else to find us:
Web- ⁠⁠http://www.nysora.com⁠⁠ 

Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠

LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ 

Facebook- ⁠⁠facebook.com/nysora⁠⁠ 

Twitter- ⁠⁠x.com/nysora⁠⁠ 

TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ 

--------------------------------------------------------- ⁠⁠

#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠

Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

In this episode of NYSORA Podcast: Updates in Anesthesiology, Dr. Hadzic breaks down a 2025 systematic review by Dr. Nancy Abou Nafeh and colleagues, exploring whether sugammadex can truly rescue patients in 'cannot intubate, cannot ventilate' (CICV) emergencies. With a 75% success rate in reported cases but crucial limitations in timing, dosing, and airway obstruction, we explore the real-world utility of this rapid-reversal agent—and why it's not a magic bullet. Tune in for key clinical takeaways that may change how you prepare for your next high-risk airway.

Where else to find us:
Web- ⁠⁠http://www.nysora.com⁠⁠ 

Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠

LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ 

Facebook- ⁠⁠facebook.com/nysora⁠⁠ 

Twitter- ⁠⁠x.com/nysora⁠⁠ 

TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ 

--------------------------------------------------------- ⁠⁠

#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠

Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

In this episode of Updates in Anesthesiology, Dr. Hadzic unpacks a major 2025 multicenter trial by Dr. Javier Ripollés-Melchor and colleagues, exploring whether the Hypotension Prediction Index (HPI) can actually reduce postoperative acute kidney injury (AKI) in abdominal surgery. Despite HPI’s promise in predicting intraoperative hypotension, the trial found no reduction in AKI or overall complications compared to standard care. We break down what this means for your practice, how vasopressor choice might matter more than prediction tools, and why clinical judgment still reigns supreme in the OR. Stay tuned for the key takeaways and what to do with that HPI alert next time it flashes on your monitor.

Where else to find us:
Web- ⁠⁠http://www.nysora.com⁠⁠ 

Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠

LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ 

Facebook- ⁠⁠facebook.com/nysora⁠⁠ 

Twitter- ⁠⁠x.com/nysora⁠⁠ 

TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ 

--------------------------------------------------------- ⁠⁠

#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠

Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

In this episode of Updates in Anesthesiology, Dr. Hadzic explores the ongoing role of neuraxial anesthesia in hip fracture surgery following the widely publicized REGAIN and RAGA trials. Despite claims of equivalence between general and neuraxial techniques, Dr. Alexander Stone and colleagues argue that these trials may have lacked the statistical power and mechanistic clarity to support such a conclusion. We break down the clinical benefits of neuraxial anesthesia—like reduced pulmonary complications, VTE risk, and opioid use—and discuss why abandoning it as a default choice could be a misstep. Tune in for practical, evidence-based insights that help anesthesiologists personalize care and keep patient outcomes front and center.

Where else to find us:
Web- ⁠⁠http://www.nysora.com⁠⁠ 

Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠

LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ 

Facebook- ⁠⁠facebook.com/nysora⁠⁠ 

Twitter- ⁠⁠x.com/nysora⁠⁠ 

TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ 

--------------------------------------------------------- ⁠⁠

#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠

Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

In this episode of UPDATES IN ANESTHESIOLOGY, Dr. Hadzic breaks down a 2025 systematic review on hyperkalemia treatment strategies. Spoiler: Insulin + glucose and beta2-agonists lower potassium fast, but the role of calcium chloride and bicarbonate isn’t as solid as once thought—especially during cardiac arrest. Tune in to learn what the evidence says, how it should reshape your clinical practice, and why some traditional therapies may need rethinking.

Where else to find us:
Web- ⁠⁠http://www.nysora.com⁠⁠ 

Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠

LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ 

Facebook- ⁠⁠facebook.com/nysora⁠⁠ 

Twitter- ⁠⁠x.com/nysora⁠⁠ 

TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ 

--------------------------------------------------------- ⁠⁠

#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠

Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

In this episode of the NYSORA Podcast, Dr. Hadzic dives into a groundbreaking study by Kapoor et al. (Anesthesiology, 2025) on extracorporeal cardiopulmonary resuscitation (ECPR) for perioperative cardiac arrest. The study reveals impressive survival rates (57.6%) and excellent neurologic outcomes (89.5%) with ECMO use in carefully selected patients. Learn how early ECMO activation, shorter CPR times, and metabolic markers can improve outcomes—and what this means for anesthesiologists and critical care teams.

Tune in for key takeaways, practical recommendations, and a glimpse into the future of perioperative resuscitation! 

Where else to find us:
Web- ⁠⁠http://www.nysora.com⁠⁠ 

Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠

LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ 

Facebook- ⁠⁠facebook.com/nysora⁠⁠ 

Twitter- ⁠⁠x.com/nysora⁠⁠ 

TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ 

--------------------------------------------------------- ⁠⁠

#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠

Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

In this episode of Updates in Anesthesiology, Dr. Hadzic unpacks the groundbreaking PRECISe trial, a major study published in The Lancet that challenges the long-standing belief that higher protein intake benefits critically ill patients. Contrary to expectations, patients receiving high-protein enteral nutrition (2.0 g/kg/day) had worse long-term quality of life and no functional recovery advantage compared to those on standard protein intake (1.3 g/kg/day).

We break down the key findings, clinical implications, and why this research might reshape ICU nutrition guidelines. Should we rethink the "more is better" approach to protein in the critically ill? Tune in to find out! 

Where else to find us:
Web- ⁠⁠http://www.nysora.com⁠⁠ 

Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠

LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ 

Facebook- ⁠⁠facebook.com/nysora⁠⁠ 

Twitter- ⁠⁠x.com/nysora⁠⁠ 

TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ 

--------------------------------------------------------- ⁠⁠

#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠

Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

In this episode of the NYSORA Podcast: Updates in Anesthesiology, Dr. Hadzic explores the latest evidence on gastric emptying in pregnancy and its implications for anesthesia, based on a 2025 review by Jacob Lawson et al., published in the British Journal of Anaesthesia.

Key topics include:
✅ How gastric emptying changes across pregnancy and postpartum
✅ The impact of opioids, epidurals, and spinal anesthesia on gastric motility
✅ Whether fasting guidelines for cesarean delivery need to be revised
✅ The role of gastric ultrasound in assessing aspiration risk

New research challenges old assumptions about aspiration risk in pregnancy, and we discuss how anesthesia providers can optimize patient safety while improving comfort.

Tune in to stay ahead of the latest updates in obstetric anesthesia!

Where else to find us:
Web- ⁠⁠http://www.nysora.com⁠⁠ 

Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠

LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ 

Facebook- ⁠⁠facebook.com/nysora⁠⁠ 

Twitter- ⁠⁠x.com/nysora⁠⁠ 

TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ 

--------------------------------------------------------- ⁠⁠

#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠

Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

n this episode of the NYSORA Podcast: Updates in Anesthesiology, Dr. Hadzic unpacks the 2025 ASA Practice Advisory on Perioperative Care of Older Adults, published in Anesthesiology and led by Dr. Frederick Sieber from Johns Hopkins. With the aging population growing rapidly, anesthesiologists must be prepared to manage frailty, cognitive impairment, and postoperative delirium in older surgical patients.

We cover practical recommendations for preoperative assessment, intraoperative anesthetic choices, and postoperative strategies to optimize recovery and preserve independence. Key highlights include:
✅ The importance of screening for frailty and cognitive impairment
✅ Neuraxial vs. general anesthesia—what does the latest evidence say?
✅ Dexmedetomidine for delirium prevention: promising or problematic?
✅ Medications to avoid in older adults
✅ The future of prehabilitation in perioperative medicine

Join us as we break down the latest evidence and how to apply it in clinical practice. Don’t miss this essential update for anesthesiologists, surgeons, and perioperative care providers!

Where else to find us:
Web- ⁠⁠http://www.nysora.com⁠⁠ 

Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠

LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ 

Facebook- ⁠⁠facebook.com/nysora⁠⁠ 

Twitter- ⁠⁠x.com/nysora⁠⁠ 

TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ 

--------------------------------------------------------- ⁠⁠

#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠

Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

Could buprenorphine be the game-changer for postoperative pain management? In this episode of Updates in Anesthesiology, Dr. Hadzic breaks down an important meta-analysis from Regional Anesthesia & Pain Medicine that compares buprenorphine to full agonist opioids. Discover why this partial agonist may offer superior pain relief, longer-lasting effects, and a safer profile—all while reducing opioid-related harm. Tune in to stay ahead of the curve! 

Where else to find us:
Web- ⁠⁠http://www.nysora.com⁠⁠ 

Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠

LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ 

Facebook- ⁠⁠facebook.com/nysora⁠⁠ 

Twitter- ⁠⁠x.com/nysora⁠⁠ 

TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ 

--------------------------------------------------------- ⁠⁠

#nysora⁠⁠⁠⁠#regionalanesthesia⁠⁠⁠⁠#anesthesia⁠⁠

Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.